HC Wainwright Has Bearish Outlook for DTIL FY2024 Earnings

Precision BioSciences, Inc. (NASDAQ:DTIL) – Equities researchers at HC Wainwright cut their FY2024 earnings per share estimates for shares of Precision BioSciences in a report released on Tuesday, November 5th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($1.23) per share for the year, down from their prior estimate of $0.82. HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is $0.82 per share. HC Wainwright also issued estimates for Precision BioSciences’ Q4 2024 earnings at ($0.42) EPS, Q1 2025 earnings at ($0.38) EPS and FY2025 earnings at ($1.05) EPS.

Precision BioSciences Trading Up 0.2 %

Shares of DTIL stock opened at $8.42 on Thursday. The stock has a market capitalization of $60.88 million, a price-to-earnings ratio of 140.36 and a beta of 1.71. Precision BioSciences has a 12-month low of $7.97 and a 12-month high of $19.43. The stock’s 50-day moving average price is $9.27 and its 200-day moving average price is $10.04.

Hedge Funds Weigh In On Precision BioSciences

An institutional investor recently bought a new position in Precision BioSciences stock. Janus Henderson Group PLC purchased a new stake in Precision BioSciences, Inc. (NASDAQ:DTIL) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 573,052 shares of the company’s stock, valued at approximately $7,739,000. Janus Henderson Group PLC owned 8.29% of Precision BioSciences as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.